Timothy Richard Rebbeck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Timothy Richard Rebbeck has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Hari Subramaniam Iyer
Section of Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, USA
82 shared publications - Kevin H. Kensler
Department of Population Health Sciences, Weill Cornell Medicine, New York, USA
70 shared publications - Charlotte Roscoe
Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts
66 shared publications - Francine Laden
Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
53 shared publications - Jaime E. Hart
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
52 shared publications - Lorelei A. Mucci
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
50 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (6)
Determinants of prostate-specific antigen levels in African men
Background: Prostate-specific antigen (PSA) is widely used for screening and diagnosis of prostate cancer. Variation in PSA levels is influenced by age, genetics, and other factors, yet this variation has not been well characterized in African men. Methods: We used data on serum PSA extracted from medical records from prostate cancer cases and controls collected as part of the Men of African Descent and Carcinoma of the Prostate (MADCaP) network. We evaluate the association of PSA levels with country of origin, age, body mass index (BMI), and polygenic risk score. Results: The median PSA levels were 41.8 (0.2-9696) ng/mL in 1907 prostate cancer cases and 1.235 (0.01-9.72) ng/mL in 902 controls. Higher PSA levels were associated with increasing age, lower BMI, higher Gleason score, and more advanced tumor stage in cases, explaining approximately 35% of variation in log-transformed PSA levels. In controls, 4.8% of PSA variation was explained by age. Conclusion: Our data in African men are consistent with non-African studies that report PSA levels increase with age, inversely with BMI (suggesting a PSA dilution effect or reverse causation), and with more aggressive disease in cases. These data may be used to help understand PSA distributions and in the future may guide screening practices in African men.
- 2 November 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (6)
Open AccessDeterminants of prostate-specific antigen levels in African men
Background: Prostate-specific antigen (PSA) is widely used for screening and diagnosis of prostate cancer. Variation in PSA levels is influenced by age, genetics, and other factors, yet this variation has not been well characterized in African men. Methods: We used data on serum PSA extracted from medical records from prostate cancer cases and controls collected as part of the Men of African Descent and Carcinoma of the Prostate (MADCaP) network. We evaluate the association of PSA levels with country of origin, age, body mass index (BMI), and polygenic risk score. Results: The median PSA levels were 41.8 (0.2-9696) ng/mL in 1907 prostate cancer cases and 1.235 (0.01-9.72) ng/mL in 902 controls. Higher PSA levels were associated with increasing age, lower BMI, higher Gleason score, and more advanced tumor stage in cases, explaining approximately 35% of variation in log-transformed PSA levels. In controls, 4.8% of PSA variation was explained by age. Conclusion: Our data in African men are consistent with non-African studies that report PSA levels increase with age, inversely with BMI (suggesting a PSA dilution effect or reverse causation), and with more aggressive disease in cases. These data may be used to help understand PSA distributions and in the future may guide screening practices in African men.
- Open Access
- 21 October 2026
- Published by Elsevier in The Lancet Regional Health - Africa
The emerging landscape of cancer genomics in Africa: a narrative review of progress, initiatives, and the path forward
- 21 October 2026
- Published by Elsevier in The Lancet Regional Health - Africa
Open AccessThe emerging landscape of cancer genomics in Africa: a narrative review of progress, initiatives, and the path forward
- 22 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3541-3542
Some answers, more questions for multi-cancer early detection tests
- 22 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3541-3542
Some answers, more questions for multi-cancer early detection tests
- Open Access
- 30 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program
Background: Men seeking care in the Veterans Health Administration (VHA) may have higher prostate cancer (PCa) incidence, metastases, and mortality (PCSM) relative to the general US population due to military exposures and increased access to care. We compared rates in both populations using contemporary databases. Methods: Annual PCa incidence, metastasis, and PCSM rates between 2008 and 2022 were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program and calculated from the VA Multi-OMICS Analysis Platform for Prostate Cancer (VA-MAPP) database. Age-adjusted rates per 100,000 were standardized to the veteran’s age distribution and stratified by race/ethnicity and age group (<50, 50-64, 65+ years). Joinpoint regression was used to evaluate trends in rates following changes in United States Preventive Services Task Force (USPSTF) screening recommendations. Results: PCa incidence and PCSM rates were higher in the VHA vs SEER (RR2018-2022: 3.34, 95% CI: 3.32-3.36). However, metastatic rates were lower in the VHA compared to SEER (RR2018-2022: 0.69, 95% CI: 0.67-0.71). PCa incidence declined in the VHA (APC2008-2011: 7.3, 95% CI: 5.0-9.6) and SEER (APC2008-2011: 3.2, 95% CI: 0.7-5.6) prior to USPSTF 2012 guidelines, but metastatic rates increased in the VHA (APC2012-2017: 4.6, 95% CI: 2.1-7.1) and SEER (APC2012-2017: 3.3, 95% CI: 1.5-5.3), followed by general flattening of incidence, metastasis, and PCSM in both groups. Conclusions: Higher PCa incidence and PCSM was observed in VHA compared to SEER, but not metastasis. Impact: Increased access to care could explain higher incidence but more favorable metastatic presentation in VHA compared to SEER.
- 30 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
Open AccessA Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program
Background: Men seeking care in the Veterans Health Administration (VHA) may have higher prostate cancer (PCa) incidence, metastases, and mortality (PCSM) relative to the general US population due to military exposures and increased access to care. We compared rates in both populations using contemporary databases. Methods: Annual PCa incidence, metastasis, and PCSM rates between 2008 and 2022 were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program and calculated from the VA Multi-OMICS Analysis Platform for Prostate Cancer (VA-MAPP) database. Age-adjusted rates per 100,000 were standardized to the veteran’s age distribution and stratified by race/ethnicity and age group (<50, 50-64, 65+ years). Joinpoint regression was used to evaluate trends in rates following changes in United States Preventive Services Task Force (USPSTF) screening recommendations. Results: PCa incidence and PCSM rates were higher in the VHA vs SEER (RR2018-2022: 3.34, 95% CI: 3.32-3.36). However, metastatic rates were lower in the VHA compared to SEER (RR2018-2022: 0.69, 95% CI: 0.67-0.71). PCa incidence declined in the VHA (APC2008-2011: 7.3, 95% CI: 5.0-9.6) and SEER (APC2008-2011: 3.2, 95% CI: 0.7-5.6) prior to USPSTF 2012 guidelines, but metastatic rates increased in the VHA (APC2012-2017: 4.6, 95% CI: 2.1-7.1) and SEER (APC2012-2017: 3.3, 95% CI: 1.5-5.3), followed by general flattening of incidence, metastasis, and PCSM in both groups. Conclusions: Higher PCa incidence and PCSM was observed in VHA compared to SEER, but not metastasis. Impact: Increased access to care could explain higher incidence but more favorable metastatic presentation in VHA compared to SEER.
- Open Access
- 15 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600021
Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.
Tumor comprehensive genomic profiling (CGP) has revolutionized cancer care and identifies patients for biomarker-specific therapy. In metastatic hormone-sensitive prostate cancer (mHSPC), although individual genes are prognostic, no comprehensive genomic classification exists using CGP that accounts for combinations of alterations to inform prognosis. We developed a DNA-based CGP classification that is prognostic for overall survival (OS) and could inform treatment. This was a retrospective cross-sectional study using multivariable models to develop a clinicogenomic prognostic risk classification in US veterans with synchronous mHSPC. The primary outcome was OS from time of metastasis. A total of 7,201 veterans with metastatic prostate cancer and CGP were identified. There were 2,484 veterans (median [IQR] age, 72 [67-77] years) with synchronous mHSPC and tissue CGP, which were divided into training and testing data sets. Sixteen genes associated with survival were identified, and favorable, intermediate, and unfavorable genomic prognostication groups were created based on the mortality risk to generate the Somatic Tumor Risk Assessment for OS-Prostate (STRATOS-P) classification. In a multivariable model, classification into intermediate and unfavorable groups was associated with increased mortality relative to the favorable group (adjusted hazard ratio [aHR], 1.54 [95% CI, 1.33 to 1.78]; aHR, 2.37 [95% CI, 1.97 to 2.485], respectively), demonstrating an average AUC of 0.83. In an external, nonveterans validation cohort, intermediate and unfavorable classifications were associated with increased mortality (aHR, 2.45 [95% CI, 1.87 to 3.21]; aHR, 4.37 [95% CI, 3.06 to 6.22], respectively) with an AUC of 0.79. The intermediate and unfavorable genomic prognostication groups were also associated with increased mortality across multiple disease states including synchronous and metachronous diagnoses, castration resistance, and analyte type. In metastatic prostate cancer, tumor DNA genomic alterations are prognostic for OS. The STRATOS-P classification is a validated prognostic tool that has the potential to guide decision making in mHSPC.
- 15 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600021
Open AccessGenomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.
Tumor comprehensive genomic profiling (CGP) has revolutionized cancer care and identifies patients for biomarker-specific therapy. In metastatic hormone-sensitive prostate cancer (mHSPC), although individual genes are prognostic, no comprehensive genomic classification exists using CGP that accounts for combinations of alterations to inform prognosis. We developed a DNA-based CGP classification that is prognostic for overall survival (OS) and could inform treatment. This was a retrospective cross-sectional study using multivariable models to develop a clinicogenomic prognostic risk classification in US veterans with synchronous mHSPC. The primary outcome was OS from time of metastasis. A total of 7,201 veterans with metastatic prostate cancer and CGP were identified. There were 2,484 veterans (median [IQR] age, 72 [67-77] years) with synchronous mHSPC and tissue CGP, which were divided into training and testing data sets. Sixteen genes associated with survival were identified, and favorable, intermediate, and unfavorable genomic prognostication groups were created based on the mortality risk to generate the Somatic Tumor Risk Assessment for OS-Prostate (STRATOS-P) classification. In a multivariable model, classification into intermediate and unfavorable groups was associated with increased mortality relative to the favorable group (adjusted hazard ratio [aHR], 1.54 [95% CI, 1.33 to 1.78]; aHR, 2.37 [95% CI, 1.97 to 2.485], respectively), demonstrating an average AUC of 0.83. In an external, nonveterans validation cohort, intermediate and unfavorable classifications were associated with increased mortality (aHR, 2.45 [95% CI, 1.87 to 3.21]; aHR, 4.37 [95% CI, 3.06 to 6.22], respectively) with an AUC of 0.79. The intermediate and unfavorable genomic prognostication groups were also associated with increased mortality across multiple disease states including synchronous and metachronous diagnoses, castration resistance, and analyte type. In metastatic prostate cancer, tumor DNA genomic alterations are prognostic for OS. The STRATOS-P classification is a validated prognostic tool that has the potential to guide decision making in mHSPC.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background:The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer.Methods:The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process.Results:Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample.Conclusions:The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development.Impact:Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background:The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer.Methods:The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process.Results:Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample.Conclusions:The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development.Impact:Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , OF1-OF12
A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. Methods: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process. Results: Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample. Conclusions: The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. Impact: Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , OF1-OF12
A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. Methods: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process. Results: Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample. Conclusions: The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. Impact: Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1050-1054
The Rising Burden of Early-Onset Cancer: Challenges and Opportunities
Summary: Early-onset cancers are increasing globally, yet traditional research frameworks have yet to inform the epidemiologic and biological underpinnings of this trend. This perspective summarizes the current state of knowledge and prospects for a research agenda spanning epidemiology, exposure science, mechanistic studies, and federated infrastructures to address this emerging challenge.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1050-1054
The Rising Burden of Early-Onset Cancer: Challenges and Opportunities
Summary: Early-onset cancers are increasing globally, yet traditional research frameworks have yet to inform the epidemiologic and biological underpinnings of this trend. This perspective summarizes the current state of knowledge and prospects for a research agenda spanning epidemiology, exposure science, mechanistic studies, and federated infrastructures to address this emerging challenge.